141 related articles for article (PubMed ID: 21356574)
81. Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways.
Lehnhardt M; Klein-Hitpass L; Kuhnen C; Homann HH; Daigeler A; Steinau HU; Roehrs S; Schnoor L; Steinstraesser L; Mueller O
BMC Cancer; 2005 Jul; 5():74. PubMed ID: 16001973
[TBL] [Abstract][Full Text] [Related]
82. RRP12 is a crucial nucleolar protein that regulates p53 activity in osteosarcoma cells.
Choi YJ; Lee HW; Lee YS; Shim da M; Seo SW
Tumour Biol; 2016 Apr; 37(4):4351-8. PubMed ID: 26499779
[TBL] [Abstract][Full Text] [Related]
83. Carbazole alkaloids as new cell cycle inhibitor and apoptosis inducers from Clausena dunniana Levl.
Cui CB; Yan SY; Cai B; Yao XS
J Asian Nat Prod Res; 2002 Dec; 4(4):233-41. PubMed ID: 12450250
[TBL] [Abstract][Full Text] [Related]
84. Pro‑apoptotic effects of pycnogenol on HT1080 human fibrosarcoma cells.
Harati K; Slodnik P; Chromik AM; Behr B; Goertz O; Hirsch T; Kapalschinski N; Klein-Hitpass L; Kolbenschlag J; Uhl W; Lehnhardt M; Daigeler A
Int J Oncol; 2015 Apr; 46(4):1629-36. PubMed ID: 25625225
[TBL] [Abstract][Full Text] [Related]
85. [Effect of bisphosphonates on anticancer activity in prostate cancer cells].
Iguchi K
Yakugaku Zasshi; 2012; 132(9):1025-30. PubMed ID: 23023419
[TBL] [Abstract][Full Text] [Related]
86. Evaluation of the Response of HOS and Saos-2 Osteosarcoma Cell Lines When Exposed to Different Sizes and Concentrations of Silver Nanoparticles.
Michalakis K; Bakopoulou A; Papachristou E; Vasilaki D; Tsouknidas A; Michailidis N; Johnstone E
Biomed Res Int; 2021; 2021():5013065. PubMed ID: 34938808
[TBL] [Abstract][Full Text] [Related]
87. Differential effects of lovastatin on cisplatin responses in normal human mesothelial cells versus cancer cells: implication for therapy.
Shi Y; Felley-Bosco E; Marti TM; Stahel RA
PLoS One; 2012; 7(9):e45354. PubMed ID: 23028957
[TBL] [Abstract][Full Text] [Related]
88. DNA damage response and repair in osteosarcoma: Defects, regulation and therapeutic implications.
Sadoughi F; Maleki Dana P; Asemi Z; Yousefi B
DNA Repair (Amst); 2021 Jun; 102():103105. PubMed ID: 33836418
[TBL] [Abstract][Full Text] [Related]
89. Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment.
Hattinger CM; Patrizio MP; Luppi S; Magagnoli F; Picci P; Serra M
Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):299-311. PubMed ID: 30822170
[TBL] [Abstract][Full Text] [Related]
90. Nitrogen-containing bisphosphonate-loaded micro-arc oxidation coating for biodegradable magnesium alloy pellets inhibits osteosarcoma through targeting of the mevalonate pathway.
Li M; Yao M; Wang W; Wan P; Chu X; Zheng Y; Yang K; Zhang Y
Acta Biomater; 2021 Feb; 121():682-694. PubMed ID: 33220487
[TBL] [Abstract][Full Text] [Related]
91. The effects of proliferation status and cell cycle phase on the responses of single cells to chemotherapy.
Granada AE; Jiménez A; Stewart-Ornstein J; Blüthgen N; Reber S; Jambhekar A; Lahav G
Mol Biol Cell; 2020 Apr; 31(8):845-857. PubMed ID: 32049575
[TBL] [Abstract][Full Text] [Related]
92. An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas.
Guerzoni C; Amatori S; Giorgi L; Manara MC; Landuzzi L; Lollini PL; Tassoni A; Balducci M; Manfrini M; Pratelli L; Serra M; Picci P; Magnani M; Fusi V; Fanelli M; Scotlandi K
BMC Cancer; 2014 Feb; 14():137. PubMed ID: 24575739
[TBL] [Abstract][Full Text] [Related]
93. Targeted therapies in bone sarcomas.
Scotlandi K; Picci P; Kovar H
Curr Cancer Drug Targets; 2009 Nov; 9(7):843-53. PubMed ID: 20025572
[TBL] [Abstract][Full Text] [Related]
94. Disulfiram and metformin combination anticancer effect reversible partly by antioxidant nitroglycerin and completely by NF-κB activator mebendazole in hamster fibrosarcoma.
Popović KJ; Popović DJ; Miljković D; Popović JK; Lalošević D; Poša M; Čapo I
Biomed Pharmacother; 2021 Nov; 143():112168. PubMed ID: 34536762
[TBL] [Abstract][Full Text] [Related]
95. Chemotherapy induced DNA damage response: convergence of drugs and pathways.
Woods D; Turchi JJ
Cancer Biol Ther; 2013 May; 14(5):379-89. PubMed ID: 23380594
[TBL] [Abstract][Full Text] [Related]
96. Co-treatment with nitroglycerin and metformin exhibits physicochemically and pathohistologically detectable anticancer effects on fibrosarcoma in hamsters.
Popović KJ; Popović DJ; Miljković D; Popović JK; Lalošević D; Čapo I
Biomed Pharmacother; 2020 Oct; 130():110510. PubMed ID: 32707437
[TBL] [Abstract][Full Text] [Related]
97. Quantitation of gene-specific DNA damage by competitive PCR.
Fernando LP; Kurian PJ; Fidan M; Fernandes DJ
Anal Biochem; 2002 Jul; 306(2):212-21. PubMed ID: 12123658
[TBL] [Abstract][Full Text] [Related]
98. p53: a target for new anticancer drugs or a target for old drugs?
Brown R
Ann Oncol; 1993 Sep; 4(8):623-9. PubMed ID: 8240992
[No Abstract] [Full Text] [Related]
99. Caffeine induces metformin anticancer effect on fibrosarcoma in hamsters.
Popović DJ; Lalošević D; Miljković D; Popović KJ; Čapo I; Popović JK
Eur Rev Med Pharmacol Sci; 2018 Apr; 22(8):2461-2467. PubMed ID: 29762853
[TBL] [Abstract][Full Text] [Related]
100. Diclofenac and metformin synergistic dose dependent inhibition of hamster fibrosarcoma, rescued with mebendazole.
Popović DJ; Popović KJ; Miljković D; Popović JK; Lalošević D; Poša M; Dolićanin Z; Čapo I
Biomed Pharmacother; 2023 Nov; 167():115528. PubMed ID: 37738800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
